Product image of Meriofert Kit (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert Kit

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert Kit (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredients in Meriofert Kit, are gonadotropins presented as an injectable kit for intramuscular or subcutaneous use. They are employed to treat infertility caused by anovulation and to support controlled ovarian stimulation in assisted reproductive technologies.

GNH India supplies Meriofert Kit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Customers benefit from comprehensive regulatory support and timely delivery across EU and global markets.

Manufacturer / TM Owner

Ibsa Pharma Kft

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert Kit, a gonadotropin preparation, is used in reproductive endocrinology to stimulate ovarian follicle development.

  • Infertility due to anovulation: induces follicular growth and ovulation to improve chances of conception.
  • Controlled ovarian stimulation for IVF: supports the development of multiple mature follicles for egg retrieval in in‑vitro fertilisation cycles.
  • Ovulation induction for intrauterine insemination (IUI): enhances follicular response to increase the likelihood of successful insemination.

How It Works

  • The preparation contains recombinant follicle‑stimulating hormone (FSH) and luteinising hormone (LH) which bind to their respective G‑protein‑coupled receptors on ovarian granulosa and theca cells. Activation of FSH receptors promotes granulosa cell proliferation, aromatase activity and estradiol synthesis, while LH receptor stimulation triggers theca cell androgen production and final follicular maturation, culminating in ovulation and prepares the endometrium for implantation.

Side Effects

Administration of Meriofert Kit may be associated with a range of adverse reactions.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the site of administration.
  • Headache: transient headache occurring shortly after dosing.
  • Nausea: mild gastrointestinal upset.
  • Ovarian hyperstimulation symptoms: abdominal bloating, mild pelvic discomfort.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (OHSS): severe fluid shift, ascites, thromboembolism.
  • Allergic reaction: rash, urticaria, or anaphylaxis.
  • Visual disturbances: blurred vision or retinal changes.

Precautions & Warnings

Clinicians should consider several precautions when prescribing Meriofert Kit to ensure patient safety.

  • Patient selection: assess baseline ovarian reserve and contraindications before initiating therapy.
  • Monitoring: perform regular ultrasound and estradiol measurements to detect excessive response.
  • Hormone-sensitive conditions: avoid use in patients with active estrogen‑dependent tumors.
  • Thromboembolic risk: evaluate history of clotting disorders as gonadotropins may increase risk.
  • Medication interactions: review concurrent use of hormonal contraceptives or other fertility drugs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert Kit can interact with other agents that affect hormonal balance or ovarian response.

Major Interactions (Avoid)

  • Hormonal contraceptives: may blunt the ovarian response and reduce efficacy.
  • GnRH agonists/antagonists: concurrent use can lead to unpredictable follicular development.

Moderate Interactions (Monitor Closely)

  • Thyroid hormone therapy: gonadotropins may alter thyroid function tests.
  • Anticoagulants: increased risk of ovarian cyst rupture may require monitoring.
  • Aromatase inhibitors: may affect estradiol levels and require dose adjustment.

Frequently Asked Questions

Meriofert Kit is prescribed to stimulate ovarian follicle development in women with infertility caused by anovulation and to support controlled ovarian stimulation during assisted reproductive technology procedures such as in‑vitro fertilisation.

FSH binds to receptors on granulosa cells, promoting their proliferation and estradiol production, while LH binds to receptors on theca cells, stimulating androgen synthesis and final follicular maturation. Together they coordinate the hormonal cascade that leads to ovulation.

The dose of Meriofert Kit is individualized by the treating physician based on the patient’s ovarian reserve, response to prior stimulation, and the specific assisted reproduction protocol. No standard dosing can be provided without a medical prescription.

Meriofert Kit is intended for use before conception to achieve pregnancy. It is not recommended for use during an established pregnancy, and safety during breastfeeding has not been established. Physicians should evaluate risks and benefits before prescribing.

To order, submit an enquiry on the Meriofert Kit product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Meriofert Kit combines both recombinant FSH and LH in a single injectable kit, offering a convenient option for protocols that require both hormones. Some alternatives provide only FSH or use urinary‑derived preparations; the choice depends on clinical protocol, patient response, and physician preference.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must never be frozen or shaken. It should be kept in its original packaging until use to maintain stability and potency.

Meriofert Kit is administered by a trained healthcare professional via intramuscular or subcutaneous injection, typically in the abdominal wall or thigh. The injection site should be rotated according to standard clinical practice to minimize local reactions.

The most serious risk is ovarian hyperstimulation syndrome (OHSS), which can cause rapid fluid shifts, abdominal distension, and in severe cases, thromboembolic events. Early recognition of symptoms and regular monitoring are essential to mitigate this risk.

Meriofert Kit is contraindicated in women with known hypersensitivity to its components, active estrogen‑dependent tumors, uncontrolled thyroid disease, severe ovarian cysts, or a history of severe OHSS. It should also be avoided in patients with significant cardiovascular or thromboembolic disorders unless specifically approved by a specialist.

Medically reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry), GNH India Pharmaceuticals Limited · Reviewed 8 Sep 2026

Published by GNH India Pharmaceuticals Limited · Last updated

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT